Gapping down
In reaction to disappointing earnings/guidance: OLN -22.2%, SKX -15.5%, ATHN -11.1%, P -7.2%, ALV -7.1%, FLEX-5.6%, GEL -5.4% (also commences registered underwritten public offering of 8 mln common units representing limited partner interests), SWKS -3.9%, PYPL -3.8%, COF -2.9%, SBUX -2.7%, GE -2.1%, CMG -1.8%, HON -1.6%, T -0.8%.
Other news:
In reaction to disappointing earnings/guidance: OLN -22.2%, SKX -15.5%, ATHN -11.1%, P -7.2%, ALV -7.1%, FLEX-5.6%, GEL -5.4% (also commences registered underwritten public offering of 8 mln common units representing limited partner interests), SWKS -3.9%, PYPL -3.8%, COF -2.9%, SBUX -2.7%, GE -2.1%, CMG -1.8%, HON -1.6%, T -0.8%.
Other news:
- HTBX -25.2% (announces an underwritten public offering of common stock for an undisclosed amount of shares)
- CFRX -19.3% (proposed underwritten public offering of common stock and warrants; terminates its sales agreement with Cowen and Company effective August 1, names Steven Gilman, PhD Chief Executive Officer effective immediately)
- MCF -16% (entered into an agreement with a private oil and gas co to purchase one-half of seller's interests in ~12,100 gross undeveloped acres for up to $25 mln Southern Delaware Basin Acreage; commences 5 mln common stock offering)
- OPTT -8.9% (announces proposed public offering of common stock and warrants)
- BLIN -5.8% (discloses entry into a securities purchase agreement to sell an aggregate of 2,100,001 shares of common stock at $0.75/share)
- VRX -2.8% (receives Complete Response Letter from the FDA regarding the New Drug Application for latanoprostene bunod ophthalmic solution)
- BRKR -2.1% (still checking)
- BA -1.5% (will record $2.1 bln in Q2 charges on 787, air cargo and KC-46 programs; reaffirms FY16 sales)
Analyst comments:
- TWTR -1.6% (downgraded to Mkt Perform from Outperform at Raymond James)
- FB -1.0% (downgraded to Neutral from Buy at BTIG Research)